Metagenomi
Latest round
- Series B
Last raised
- Jan 2023
Total raised
- $376M
Investors
- 23
About Metagenomi
, operates as a gene-editing system that provides analytics solutions using machine learning for treating genetic diseases. The company was founded by Brian Thomas and Jillian Banfield.25 million shares at USD 15 per share, at the expected USD 15-17 range, on the Nasdaq Global Select Market under the ticker symbol "MGX". The company provides a CRISPR-based system that focuses on the development and research of cell and gene therapies for genetic diseases such as Cystic fibrosis, Sickle-cell anemia, and Marfan syndrome. Metagenomi, Inc. plans to expand its team and development of its therapeutic pipeline.
Who invested in Metagenomi
23 investors across 6 rounds
See all investors in Metagenomi
Sign up free to see every VC on the cap table, the rounds they joined, and how much each round raised.
Questions about Metagenomi
Who invested in Metagenomi?
Metagenomi has 23 investors on record across 6 venture rounds. Sign up free to see every VC on the cap table and the rounds they joined.
How much funding has Metagenomi raised?
Metagenomi has raised 6 venture rounds. Sign up free to see how much each round raised and the total.
When did Metagenomi last raise money?
Metagenomi's most recent round on record is a Series B, in Jan 2023.
What does Metagenomi do?
, operates as a gene-editing system that provides analytics solutions using machine learning for treating genetic diseases.
Where is Metagenomi headquartered?
Metagenomi is headquartered in Emeryville, US.
Which VCs invest in companies like Metagenomi?
Among active investors with capital left to deploy, Andreessen Horowitz, Founders Fund, Accel and Thrive Capital back biotechnology companies at Metagenomi's stage. Their profiles are linked below.
VCs backing biotechnology startups at Series B
Raising like Metagenomi? Find the right VCs.
Capital Atlas matches your startup to active investors by stage, sector and region.